Your ideal pharma partner, from China.
Book Your Ideal Products and Service from China
Based in Shanghai, BOOKPHARM is a pharmaceutical company built on a professional team with more than seventeen years in the industry. We work across high-tech biological products (finished dosage forms, active pharmaceutical ingredients and advanced intermediates) and provide the services around them: technology transfer, CDMO/CMO, and regulatory support.
We have co-established a biotechnology R&D lab in Shanghai and GMP manufacturing in Anhui province. Our strengths span insulins, GLP-1 peptides, monoclonal-antibody biosimilars, and a broad small-molecule API catalog, backed by the regulatory filings that let our partners build on our supply with confidence.
Having worked with more than 200 pharmaceutical partners worldwide, we continue to invest in ESG and aim to bring reliable products and service to partners across the US, EU, Asia, Latin America and the Middle East.
- Founded on
- A professional pharma team, 17+ years
- R&D lab
- Shanghai, China
- GMP manufacturing
- Anhui province
- Reach
- 200+ partners · 40+ countries
- Focus
- ~80% API supply; remainder FDF & supplements
- Markets
- US · EU · Asia · LATAM · MENA · China
The manufacturers behind the supply.
We work with established manufacturing partners in China. Each holds its own certifications and files its own dossiers.
Manufacturing partner supplying active pharmaceutical ingredients and intermediates, based in Deqing, Zhejiang, China. Established 1999, FDA-certified since 2007. The site runs a provincial technology research and development centre and has since added Japanese PMDA, Korean MFDS and Chinese GMP certification.
- Established
- July 1999
- Site
- 59,050 m², 38,000 m² built
- Approvals
- US FDA (2007), PMDA, MFDS, China GMP
- Team
- 168 staff, 69 technical specialists
Manufacturing partner for insulin and GLP-1 peptides, operating a cGMP biomanufacturing facility in Jiaxing, near Shanghai. Its vertically integrated platform covers recombinant insulins, semaglutide in injectable and oral grades, and recombinant enzymes, with aseptic filling for vials, cartridges and pre-filled syringes.
- Site
- 920,000 sq ft cGMP biomanufacturing
- Peptide API
- 3 tonnes per year, expandable to 10
- Fill and finish
- 140 million units per year
- Focus
- Insulins, GLP-1 peptides, recombinant enzymes
Manufacturing partner for GLP-1 peptides and specialty APIs, based in Chongqing International Biological City, FDA-qualified. It runs a peptide platform for semaglutide, tirzepatide and retatrutide alongside a small-molecule platform for high-potency APIs and ADC compounds.
- Founded
- 2016
- Site
- 55,333 m² FDA-qualified
- Team
- 300+ staff
- Inspections
- US FDA, PMDA, ANSM, TGA
Manufacturing partner for peptide APIs, providing one-stop CMC services from process development and pilot scale-up through cGMP commercial supply. Its Shanghai platform covers linear, modified and cyclic peptides, with regulatory support for DMF, IND and NDA filings.
- Location
- Songjiang, Shanghai
- R&D line
- 10 kg per year
- Pilot lines
- Two lines, 100 kg per year
- Scope
- Preclinical through commercial cGMP
Sourcing, manufacturing and the regulatory work in between.
We book capacity across a vetted manufacturer network, then carry the project through filing and delivery. These are the services we run for B2B buyers.
- 01API supply
- 02FDF (finished dosage form) supply
- 03Advanced intermediates supply
- 04CDMO / CMO (API + FDF, incl. GCT: viral vector & cell therapy)
- 05Technology Transfer / Registration / Supply
- 06License-in / License-out (BD)
- 07GMP & RA (Regulatory Affairs) consulting for EU, US, Brazil and Mexico markets
- 08International M&A consulting
Six lines, one catalog.
A broad small-molecule API catalog, roughly 80% of what we supply.
Semaglutide, tirzepatide and retatrutide among others, with specification sheets.
Insulin analogues and monoclonal-antibody biosimilars through our partner network.
Oligonucleotide APIs produced on dedicated capacity.
China's first injectable-grade NAD+ supply, available as API and finished pen.
FDF supply and peptide nasal-spray formats for selected markets.
Tell us what you need to source.
No prices are published. We quote by inquiry to qualified B2B buyers.